Cancers | Free Full-Text | Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
B-cell receptor signaling in diffuse large B-cell lymphoma. | Semantic Scholar
Diffuse large B-Cell lymphoma: from novel molecular classifications to tailored targeted therapies
Pathogenetic signaling pathways in diffuse large B-cell lymphoma... | Download Scientific Diagram
Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma: Molecular Therapy - Oncolytics
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
Treatment resistance in diffuse large B-cell lymphoma | Leukemia
JCI Insight - Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
Preventing central nervous system spread in diffuse large B-cell lymphoma – novel approaches needed | Haematologica
Frontiers | The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
NIH study revises molecular classification for most common type of lymphoma | National Institutes of Health (NIH)
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Trial results show that younger lymphoma patients respond well to ibrutinib | Center for Cancer Research
Gene Expression Affects Treatment Response With Ibrutinib in Patients With Diffuse Large B-Cell Lymphoma - Hematology Advisor
Ibrutinib improves diffuse large B-cell lymphoma survival - NCI
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study - eClinicalMedicine
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
AbbVie, Johnson & Johnson's Imbruvica comes up short in non-Hodgkin lymphoma trial | Fierce Pharma
Overall survival following Richter transformation on ibrutinib by line... | Download Scientific Diagram
Frontiers | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas
Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma | Immunotherapy
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
The key signaling pathways implicated in diffuse large B cell lymphoma... | Download Scientific Diagram
Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
The clinical picture of primary cutaneous diffuse large B-cell... | Download Scientific Diagram
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
